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ARTICLE
Data Digitizing: Accurate and Precise Data Extraction for 
Quantitative Systems Pharmacology and Physiologically-
Based Pharmacokinetic Modeling
Jan-Georg Wojtyniak1,2, Hannah Britz1, Dominik Selzer1, Matthias Schwab2,3,4 and Thorsten Lehr1,*
In quantitative systems pharmacology (QSP) and physiologically-based pharmacokinetic (PBPK) modeling, data digitizing is 
a valuable tool to extract numerical information from published data presented as graphs. To quantify their relevance, a lit-
erature search revealed a remarkable mean increase of 16% per year in publications citing digitizing software together with 
QSP or PBPK. Accuracy, precision, confounder influence, and variability were investigated using scaled median symmetric 
accuracy (ζ), thus finding excellent accuracy (mean ζ = 0.99%). Although significant, no relevant confounders were found 
(mean ζ ± SD circles = 0.69% ± 0.68% vs. triangles = 1.3% ± 0.62%). Analysis of 181 literature peak plasma concentration 
values revealed a considerable discrepancy between reported and post hoc digitized data with 85% having ζ > 5%. Our find-
ings suggest that data digitizing is precise and important. However, because the greatest pitfall comes from pre-existing 
errors, we recommend always making published data available as raw values.
During the past few years, quantitative systems phar-
macology (QSP) and especially physiologically-based 
pharmacokinetics modeling (PBPK) have proven to be an 
important cornerstone of model-informed drug discov-
ery and development.1 However, for model development, 
time-dependent data of pharmacological relevant pro-
cesses are a crucial requirement. Unfortunately, published 
data are typically presented in aggregate form as plots or 
graphs without providing access to the underlying raw, un-
condensed data. As a result, researchers must extract the 
information of interest from the graphical representation to 
use the data for their modeling approaches. Despite the 
potential to automatically data-mine population average 
pharmacokinetic (PK) data for certain applications,2 data 
extraction from graphical representations still requires man-
ual efforts. To illustrate the scale of this issue, it should be 
noted that PBPK projects not uncommonly rely on extracted 
data gathered from up to 50 articles.3–9 Fortunately, several 
off-the-shelf digitization software packages that allow the 
extraction of numerical information from their two-dimen-
sional graphical representation are currently available.10–13 
These software solutions have been in active use for some 
time for the well-established population PK approaches.14 
However, neither for them nor for QSP or PBPK modeling is 
information available regarding the importance and use of 
digitizing software. Moreover, to the best of our knowledge, 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  In quantitative systems pharmacology (QSP) and 
physiologically-based pharmacokinetic (PBPK) modeling, 
data digitizer becomes a valuable tool to translate litera-
ture data from a graphical representation into numerical 
values.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  This study investigated the usage of digitizing software 
in QSP and PBPK modeling. Moreover, it evaluated the 
software accuracy, precision, confounder influence, and 
variability between software. In addition, the discrepan-
cies between reported and graphically presented data 
were analyzed.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  The results of this study contributed to an im-
proved  understanding of the precision and accuracy of 
digitizing software.
HOW MIGHT THIS CHANGE DRUG DISCOVERY, DE-
VELOPMENT, AND/OR THERAPEUTICS?
✔  The study findings could help improve the quality of the 
QSP and PBPK models, which were developed based on dig-
itized literature data. Furthermore, they can protect the mod-
eler from using biased data that could subsequently lead to 
false in silico predictions and hence hamper the drug discov-
ery and development process or, even worse, harm patients 
as a result of erroneously derived therapy recommendations.
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there is no systematic evaluation of the accuracy and pre-
cision of these software solutions, nor have any interfering 
factors that could potentially bias the digitized output been 
identified. In addition, little is known about the extent of dis-
crepancy between reported and graphically presented data 
that is typically only revealed after post hoc digitization and 
the nature of these errors and confounding factors when it 
comes to the digitization process. Consequently, these fac-
tors can potentially interfere with model development and 
evaluation processes and ultimately lead to false predic-
tions and questionable model-based decisions.
Thus, the first objective of this analysis was to assess the 
general usage of the data digitizing software for QSP and PBPK 
modeling. Second, this analysis aimed to evaluate the accuracy 
and precision of a relevant digitizing software. Moreover, dis-
crepancies between reported and graphically presented data 
were quantified, and the covariates influencing the digitizing 
process were identified. Finally, recommendations regarding 
the creation of digitizable plots and graphs and the digitization 
process itself were proposed.
METHODS
Literature search
In a first step, literature published between January 2005 and 
September 2019 were queried for terms regarding the most 
common digitizing software in combination with the two termi-
nologies “systems pharmacology” and “physiologically based 
pharmacokinetic.” For this purpose, the software Publish or 
Perish15 was used using the Google Scholar search engine for 
terminology queries. Google Scholar was used because the 
search engine allows a full-text analysis, which was a prereq-
uisite because the use of digitizing software is, in most cases, 
only mentioned in the Methods sections of texts. For each dig-
itizing software, the search query “systems pharmacology OR 
physiologically based pharmacokinetic AND software name” 
was used. The search was performed by one author (J.-G.W.) 
and reviewed by two other authors (H.B., D.S.). The search 
query results were not further edited or restricted by specific 
exclusion criteria. Moreover, no gray literature analysis was 
performed. Subsequently, the annual publications that con-
tain the terms were used as a surrogate marker of importance. 
Furthermore, Poisson regression was applied to describe 
and predict the trends in software usage from 2005 to 2021. 
Moreover, a detailed search for publications from 2012 to 2019 
in CPT: Pharmacometrics & Systems Pharmacology (CPT:PSP) 
was also performed. For this, the search query “systems phar-
macology OR physiologically based pharmacokinetic AND 
software name” was used. To identify unreported uses of 
digitization, all publications from CPT:PSP containing only the 
terms “systems pharmacology OR physiologically based phar-
macokinetic” without the name of a digitization software were 
selected. Following this, the cumulative publication frequency 
was calculated. Afterward, based on the assumption that data 
digitization is necessary for every project related to QSP or 
PBPK, the relative frequency of unreported digitizing software 
usage was estimated. Finally, to investigate the reporting rate 
of digitizing techniques in the methods, all published articles 
from CPT:PSP from 2018 were reviewed manually to identify 
articles related to PBPK that referenced a digitizing software 
and most likely had used literature data.
Software evaluation
A study was performed to assess the accuracy and pre-
cision of the digitizing software GetData Graph Digitizer10 
and to identify the interfering factors that potentially have 
an influence on the digitized output. As study inclusion cri-
teria, the subjects had to be at least 18 years old and be 
able to use the digitization software independently after 
a standardized software introduction. Furthermore, they 
had to give informed consent and, following this, were 
randomly split into two groups (group 1 and group 2). All 
subjects had to fill out a standardized questionnaire to col-
lect demographics such as age and education. They were 
asked to digitize the same steady-state plasma concentra-
tion-time graph of a hypothetical drug (two-compartment 
model, absorption constant (Ka) = 3 hour−1, plasma clear-
ance (CL)  =  4  L/hour, central volume of distribution 
(V1) = 20 L, intercompartmental clearance (Q) = 3 L/hour, 
peripheral volume of distribution (V2) = 70 L, oral bioavail-
ability (F) = 100%, dose = 1 mg simulated using Berkeley 
Madonna V 8.3.18 developed by Robert Macey and George 
Oster, University of California, Berkeley, CA) three times in 
a row. The two-compartment model was chosen as it can 
be easily parametrized and because the simulations can be 
easily reproduced. To minimize a possible bias attributed 
to learning effects, the plasma concentration-time profile in 
group 1 consists of 10 values marked as circles following 10 
values marked as triangles (sample time points: 0, 1, 2, 3, 
5, 7, 10, 13, 16, 20, 24, 25, 26, 27, 29, 31, 34, 37, 40, 44). The 
profile in group 2 was designed as triangles first and circles 
last. The random allocation sequence for the study subjects 
was generated with Excel 2016 (Microsoft, Redmond, WA) 
using a two-sized block randomization and implemented 
via consecutive questionnaire numbers. No blinding was 
performed. To validate that demographics are equally dis-
tributed within the groups, an analysis of variance (ANOVA) 
or chi-square goodness-of-fit tests were performed for 
continuous and categorical demographics, respectively. If 
the study data were missing, it was imputed with calculated 
median values for continuous variables and with calculated 
modal values for categorical variables. To evaluate a po-
tential bias attributed to missing values, statistical analyses 
were performed with and without imputed values whenever 
necessary, and the results were compared afterward.
For comparing accuracy and precision, the scaled me-
dian symmetric accuracy (ζ)16 and ζ standard deviation 
(SD) were calculated as shown in Eqs. 1–4. Scaling (mini-
mum–maximum normalization17) as depicted in Eq. 1 was 
independently performed for time and concentration values. 
ζ was calculated over the combined vector of scaled values 
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With xscaled  =  scaled value, x  =  original value, xmin  =  min-
imum of the original values, xmax  =  maximum of the original 
values, machine=machine epsilon, Qi  =  accuracy ratio, 
xscaled,digitized =  scaled digitized value, xscaled,simulated  =  scaled 
simulated value, n = number of ζ values, and xi = ζ, x = mean ζ.
Because ζ for values equal zero is not defined, the ma-
chine epsilon (2.2E-16) was added to each value. Afterward, 
the impact of demographic variables (age, sex, education, 
average computer usage per day, experience with digitizing 
software, and right-handedness) and study-specific vari-
ables (digitizing time, symbol shape, type of computer used, 
and mouse usage) on ζ were investigated using multiple lin-
ear regression. Moreover, to analyze if multiple digitization 
leads to better results, an ANOVA with different repetitions 
on ζ was performed.
The required study sample size was calculated for comparing 
two sample means with an equal variance. Because no literature 
reference values were available, a mean ζ of 5% and a variance 
of 2% for circle shapes were assumed. Furthermore, a 1.5% 
increase of ζ in the triangle group was assumed compared with 
circles. From this, the necessity of at least 62 subjects was cal-
culated to get a significant result with a statistical power of 80%, 
and a significance level of 5% and a dropout rate of 10% were 
assumed (28*2*1.1 = 61.6).
Subsequently, to investigate the impact of the use of dig-
itized data on parameter estimation, the PK parameters of 
the hypothetical drug were estimated for each of the dig-
itized profiles via nonlinear optimization using the lbfgsb3 
R package.18 Afterward, the relative deviation compared 
to the parameters used for simulation were calculated and 
visualized.
Consequently, a substudy with 14 subjects from the 
main study group was conducted to compare the accu-
racy and precision of the digitization software packages 
DataThief, Engauge Digitizer, and GetData Graph Digitizer. 
In this study, the subjects digitized the graph from group 1 
with each digitization software. Afterward, ζ and ζ SD were 
calculated for the digitized profiles and subsequently ana-
lyzed via an ANOVA and pairwise t-test. The graphs of both 
groups and an overview of the whole study procedure are 
shown in Figure 1. The three digitization software packages 
DataThief, Engauge Digitizer, and GetData Graph Digitizer 
were selected based on the criteria of software availability, 
usability, included features, and the feedback from a small 
user survey (10 subjects from our group). A comprehen-
sive list of the different digitization software features can be 
found in Table S1.
Analysis of published PK data
Finally, the extent of discrepancy between the reported 
and graphically presented data were investigated based on 
published sample time points and mean peak plasma con-
centration (Cmax) values. For this, digitized readouts as well 
as published raw values from single and multiple dose pro-
files that were previously digitized in-house with GetData 
Graph Digitizer were used. A complete list from all stud-
ies included can be found in the supplementary material in 
Tables S2 and S3. Unscaled ζ was calculated individually 
for all available values. Following this, a stepwise multivar-
iate linear regression analysis (forward inclusion P ≤ 0.05, 
backward elimination P ≤ 0.01) was performed to investi-









Figure 1 Schematic overview of the study protocol as well as the concentration-time profiles digitized by study subjects.






























Digitizing a profile three times Digitizing a profile with three different 
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document format (PDF) (scanned vs. not scanned), the 
publishing year, and the investigated parameter (Cmax or 
sample time points). In addition, for values that revealed a 
ζ greater than 5%, a root cause analysis was performed.
All graphical and statistical analysis as well as the sample 
size calculations were performed using R and R-Studio.19,20
RESULTS
Literature search
Digitizing software is increasingly used in QSP and PBPK 
modeling as shown in Figure 2a. The free and open-source 
Engauge Digitizer was most frequently cited, followed by 
the GetData Graph Digitizer (see Figure b2). For most soft-
ware, an increase in use during the analyzed time span was 
observed. Arithmetic mean increase per year was 16%, 
with the highest increase for WebPlotDigitizer (87%) and 
the highest decrease for DataThief (−8%) (see Figure S1).
The Publish or Perish search query for QSP or PBPK in 
the journal CPT:PSP from 2012 to 2019 revealed 477 publi-
cations. In contrast, for the search terms QSP or PBPK and 
the names of the most important digitization software pack-
ages, only 31 entries were found. Based on the assumption 
that every QSP or PBPK project requires the use of digitiza-
tion software, these findings led to an underreporting rate of 
94%. Figure 2c shows the cumulative number of publica-
tions for both search queries. In addition, after the manual 
review of articles published in CPT:PSP in 2018, 20 origi-
nal research articles that presented PBPK modeling results 
were found. Among those, 16 used concentration-time or 
other PK data for model development or validation. Among 
the 16 studies, 12 used literature data that most likely had 
to be digitized, 3 had access to individual level data, and 1 
study used data from a database for their model develop-
ment. Among the 12 studies that used literature information, 
17% (n = 2) reported that they had used a digitization soft-
ware, leading to an underreporting rate of 83%. A detailed 
overview of the manual review process is shown in Figure 
S2 and Table S4.
Software evaluation
Overall, 70 subjects (51% male) were enrolled in our study. 
Their mean age was 30 years (range of 18–65 years), and 
they engaged in a mean computer usage of 4.1 (±3.0) hours 
per day. Only 4% of them had worked with a digitizing soft-
ware before. All subjects had an educational degree, with 
the lowest being lower secondary school–leaving certificate 
and the highest being a doctorate. Demographic character-
istics and the number of subjects were equally distributed 
in both groups as summarized in Table 1. The ANOVA and 
chi-square goodness-of-fit tests revealed no significant dif-
ferences in study demographics between the groups, with 
Figure 2 Results from  literature search. (a)  Number of 
publications containing the terms “systems pharmacology” 
or “physiologically based pharmacokinetic” and the names 
of the digitization software packages investigated during 
the past few years. Labels and the dashed purple line shows 
model-estimated values. Solid lollipops represent the 
observed values. (b) Total number of publications containing 
the terms “systems pharmacology” or “physiologically based 
pharmacokinetic” and the name of the digitization software 
package for each package investigated. The names investigated 
were “Engauge Digitizer,” “GetData Graph Digitizer,” “Un-Scan 
it,” “WebPlotDigitizer,” “DigitizeIt,” “GraphClick,” “DataThief,” 
“Dagra,” “WinDig,” “g3data,” and “im2graph.” (c) Analysis of the 
cumulative publication frequency in CPT: Pharmacometrics & 
Systems Pharmacology of the terms “systems pharmacology” 
or “physiologically based pharmacokinetic” (blue solid line, 
triangles) when compared with “systems pharmacology” or 
“physiologically based pharmacokinetic” and the names of 
the digitization software packages (orange solid line, circles) 
investigated during the the past few years. QSP, quantitative 
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P values always greater than 0.08. The demographic infor-
mation for all study participants was complete. Thus, no 
data had to be imputed.
Mean ζ was small for all digitized profiles (0.99%), indicat-
ing excellent accuracy. Furthermore, ζ SD was low (0.72%), 
revealing a good precision of the software. The regression 
analysis revealed a significant (P  <  0.001) effect of symbol 
shape and digitizing time on ζ. These effects are visualized 
in Figure 3. Triangles had a 1.9-fold increased mean ζ when 
compared with circles (1.3% vs. 0.69%) and, hence, were less 
accurately digitized. Furthermore, subjects digitizing slowly 
were more accurate than subjects digitizing faster (Figure 3b). 
Besides that, no other covariates had a significant effect on ζ.
From the first to the last repetition, the mean digitiz-
ing time declined moderately (first, 3.01  minutes; second, 
2.24 minutes; third, 2.16 minutes). No statistical difference 
in accuracy or precision was observed between the three 
replicates as shown in Figure S3.
Furthermore, the estimated PK parameters based on the 
digitized profiles revealed only small deviations when com-
pared with the parameters used for profile simulation with a 
mean modulus of the relative deviation of 0.5%. The devia-
tion of all parameters is visualized in Figure 3c.
An ANOVA analysis of the performed substudy revealed 
statistically significant differences in accuracy and preci-
sion among the investigated software (Figure 3d). GetData 
Graph Digitizer and Engauge Digitizer had a similar mean ζ 
value (0.2%), whereas DataThief had a markedly increased 
value (0.5%). The ζ SD was 0.1%, 0.2%, and 0.4% for 
GetData Graph Digitizer, Engauge Digitizer, and DataThief, 
respectively.
Analysis of published PK data
For investigating the literature profile quality, 181 mean Cmax 
values and 3499 sample time points of concentration-time 
profiles obtained from 81 literature studies published between 
1984 and 2017, which were presented as graphs and as nu-
meric values, were analyzed. Digitization was carried out as 
part of two of our in-house model developments (simvastatin, 
ketoconazole). The digitized profiles were originally derived 
from graphs that had either linear or logarithmic scaled axes 
and were depicted either as single or panel plots. Therefore, 
3% of the sample time points and 85% of the mean Cmax val-
ues had a ζ greater than 5%. The linear regression analysis 
revealed that besides the parameter investigated (sample 
time points or Cmax), neither the PDF format (scanned vs. not 
scanned) nor the publishing year had a significant effect on ζ. 
The subsequently performed root cause analysis found for all 
sample time points with ζ greater 5% a justification, namely, 
either the x axis was not sufficiently resolved or the x axis 
in the graphic had an uneven resolution. In contrast, a rea-
son for the discrepancy could be identified in only 40% of the 
mean Cmax values with ζ greater than 5%. Specifically, they 
were caused either by poor graphic quality, incorrect labeling, 
or different types of central tendencies presented in the table 
and graphic. For the remaining digitized mean Cmax values, 
no justification could be found, leading to an assumption of 
either incorrectly stated mean Cmax values in the depicted 
concentration-time profile or in the presented table. An over-
view of the error frequencies and ζ distribution is presented 
in Figure 4.
Finally, based on the most important study findings, a 
digitization algorithm as depicted in Figure  5 was formu-




The reuse of data through digitization from published ar-
ticles  is an easy-to-use and attractive way for gathering 
necessary information, especially in QSP and PBPK mod-
eling. This is also evident in the investigated publication 
frequencies of “systems pharmacology” or “physiologi-
cally based pharmacokinetic” in combination with the 
names of the investigated digitization software solutions. 
Thus, a remarkable, constant, and exponential increase 
in the number of literature references was observed. This 
was observed not only for the pooled number of publi-
cation frequencies but also for most of the software 
packages themselves. However, it should be mentioned 
that because of the large number of different software 
solutions, it is very unlikely that all digitizing software 
available was investigated. In addition, we assume that 
the actual number of unreported digitizing software 
usage is significantly higher and that the software is often 
not reported. This is supported by the cumulative number 
of publications from 2012 to 2019 in the journal CPT:PSP, 
where 477 publications citing “systems pharmacology” or 
“physiologically based pharmacokinetic” are published 
but only 31 publications additionally mention the name of 
a digitizer software. Subsequently, even if not every pub-
lication on the subject requires digitization software, this 
still suggests a massive underreporting. This assumption 
is further validated by the manual review of publications 
Table 1 Study demographics
Parameter and descriptive measures Group 1, N = 36 Group 2, N = 34 Total, N = 70
Age, y, mean (SD) 30 (13) 30 (12) 30 (13)
Average computer usage per day, hour, mean (SD) 4.5 (3.1) 3.7 (2.9) 4.1 (3.0)
Mouse usage, count (%) 31 (86) 30 (88) 61 (87)
No experience with digitization software, count (%) 33 (92) 34 (100) 67 (96)
Right-handedness, count (%) 30 (83) 32 (94) 62 (89)
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from 2018 in CPT:PSP on PBPK modeling, revealing a re-
porting rate of 17%.
As a drawback of the performed literature search, one 
can state that the search query results were not further 
revised, and no gray literature analysis was carried out as 
recommended for systematic reviews. However, the pur-
pose of the literature search was not the development of 
a systematic and exhaustive review but, rather, the identi-
fication of general trends. For this reason, the methodology 
differs from that of a systematic review. For example, search 
Figure 3 Results from the multiple linear regression analysis.  Influence of the symbol shape (a) on median symmetric accuracy is 
visualized as a boxplot with the Wilcoxon rank sum test. Effect of digitizing time (b) on median symmetric accuracy is depicted as a 
scatterplot with linear regression formula and coefficient of determination. (c) Relative pharmacokinetic parameter deviation of the 
estimated parameters when compared with the values used for profile simulation is shown as boxplots. Parameter estimation was 
performed for each digitization run. (d) Median symmetric accuracy for different digitization software shown as boxplots. ANOVA as 
well as pairwise Wilcoxon rank sum tests were performed. ANOVA P value is stated. For Wilcoxon rank sum test P values, the following 
annotation was used: ****≤ 0.0001, **≤ 0.01; *≤ 0.05; NS > 0.05. In addition, in d arithmetic, the mean of all groups is shown as a dashed 
line. All boxplots visualize the following descriptive statistics: The median value, the interquartile range, and the 1.5-fold interquartile 
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queries were not carried out in various databases such as 
PubMed or Embase as recommended for systematic re-
views. Instead, the search engine Google Scholar was used, 
whose algorithm screens many different databases and 
sources; moreover, this is better suited to get an overview of 
the frequency of use in literature.
Nevertheless, it can be assumed that the usage of digitiz-
ing software in QSP and PBPK modeling will further increase 
in the next few years as shown in Figure 2.
Software evaluation
For the study with 70 subjects, ζ was chosen as an error met-
ric because of its intuitive interpretation as a relative error.16 
With a mean ζ of 0.99% and a mean ζ SD of 0.725%, the 
digitized readouts were tremendously accurate and precise. 
This is also reflected in the accuracy of the PK parameters 
subsequently fitted to the digitized profiles showing a mean 
modulus of relative deviation of 0.5% when compared with 
the original values. This further suggests the assumption that 
the accuracy of individual digitized values is less important 
because they are not independently analyzed in the model 
but as time-dependent series of values. Apart from this, the 
symbol shape and digitizing time revealed a significant ef-
fect on the accuracy (ζ), leading, for example, to a 1.9-fold 
lower mean ζ value for circles when compared with triangles. 
Nevertheless, these effects are still negligible, considering 
the overall small ζ. Although the average digitizing time de-
clined with each repetition, no advantages in accuracy were 
observed if the same graph was digitized more than once. 
Based on these results, we recommend that one-time, slow-
paced digitizing is sufficient for a proper readout.
The additionally performed substudy revealed significant 
differences in accuracy comparing DataThief and the two 
software products Engauge Digitizer and GetData Graph 
Digitizer. Here, DataThief showed a 1.5-fold decline in ac-
curacy when compared with Engauge Digitizer and GetData 
Graph Digitizer. As mentioned previously, this effect is still 
negligible because the mean ζ for all three software pack-
ages was still less than 0.6%. This led to the assumption 
that although significant differences between the software 
exist, accuracy is still excellent, and thus, other software 
features are more important. For example, the freely avail-
able and open-source software Engauge Digitizer is still 
under active development on GitHub, providing a wide 
range of functionalities and available in different languages 
for multiple operating systems. Although this might raise 
the question of whether, apart from the software, other fac-
tors such as the operating system also have an impact on 
Figure 4 Discrepancy between reportedand graphically presented sample time points and mean Cmax values. Relative frequency of ζ 
< 5% and justifications for ζ values ≥ 5% were presented as bar charts. Distribution of ζ values were in addition shown as boxplots. (a) 




Sample time points (N=3499)































































































Data Digitizing in QSP and PBPK Modeling
Wojtyniak et al.
Figure 5 Proposed digitization algorithm to improve the daily digitizing and graph creation practice in the fields of quantitative 
systems pharmacology and physiologically-based pharmacokinetics. Examples are taken from refs. 22 to 25. AUC0–24h, area under 




Before you start check if:
• Each axis scaling is uniformly resolved (unlike in A)
• Each axis scaling is reasonable (unlike in B)
• Graphics quality is high (unlike in C)
• Correct labeling is used























After you are done with digitization:
• Double check values which are stated as numeric values and in form 
of a graph like sampling time points or Cmax values
• Consider “correcting” your extracted data using numerically stated 
values like sampling time points.
GetData Graph DigitizerDataThief Engauge Digitizer
Check your readout
Use the data for your analysis
• Slow digitization can improve the quality of the output
• It is not necessary to digitize the same graph multiple times
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accuracy, at least for Engauge, this is very unlikely because 
it is programmed in Qt, an operating system–independent 
programming language.12,21
Analysis of published PK data
Data that were redundantly presented as numeric values 
as well as in a graphs or plots were analyzed using ζ as 
an error metric for the differences between reported values 
and the corresponding digitized graphical representation. 
If ζ was > 5%, the graphs and plots were further explored 
to determine the article properties that may impede re-
searchers from retrieving correct readouts. ζ of the digitized 
sample time points were in good agreement with the results 
derived from the previously conducted study. However, a 
few sources of errors could be identified. Specifically, the 
resolution of the axes seemed to have an important influ-
ence on the quality of the digitized readout. If one of the 
axis resolutions is uneven or the resolution does not allow 
cleanly distinguishing between individual measuring points, 
the result can be falsified. Surprisingly, with 80% of the 181 
mean Cmax values having a ζ  >  5% and a maximum ζ of 
1760%, alarmingly large differences between the published 
numerical values and the values in graphs were found. Even 
worse, as shown in Figure 4, after the performed root cause 
analysis for 40% of the Cmax values with ζ greater 5%, no 
justification could still be identified. This leads to the as-
sumption that either the wrong graph was plotted or a wrong 
Cmax was reported. Based on these findings, we strongly 
recommend that published data should additionally always 
be made available as raw data. Furthermore, if such access 
is available, digitizing reported and graphically presented 
data should be avoided; instead, raw data should be used. 
Moreover, if access to raw data is not available, researchers 
should check that each axis scaling is uniformly and opti-
mally resolved, the graphics quality is high, and the correct 
labeling is used. In addition, they should try to double check 
their digitized values based on values that are additionally 
published in a numeric form. However, although following 
the last recommendation may prevent the use of corrupted 
data, there is no option to correct the readout if the errors 
that are already present before digitization get detected. 
Consequently, it is very likely that many profiles cannot be 
reused after all. For this reason, it is hoped that in the long 
run, all data published in condensed form as graphs will 
also be made available to scientists as raw values.
In summary, it was found that digitizing software has be-
come more popular, especially in QSP and PBPK modeling. 
The presented results indicate that they are a great tool to 
gather data from graphical representations with excellent 
accuracy and precision. Moreover, neither user-dependent 
nor software-dependent relevant confounders could be 
identified. Although the digitizing time, symbol shape, and 
software used had a statistically significant influence on dig-
itizing accuracy, the impact on the routine digitizing practice 
seems negligible. Digitizing a graph more than once did not 
improve the quality of the readout and thus is redundant. 
However, it was also found that the greatest danger of incor-
rectly derived analysis results based on digitized data does 
not come from the process of digitizing but from pre-existing 
errors in the published data. Overall, the results of this study 
are the results of the first systematic investigation on the 
accuracy and precision of digitizing software. Hopefully, the 
derived recommendations as summarized in Figure 5 may 
guide and improve the daily digitizing and graph creation 
practice in the field of QSP and PBPK modeling and even-
tually enhance the quality of models developed based on 
digitized readouts.
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